0L8.F Lantheus Holdings Inc
- Market cap
- EUR 5.91B
- P/E
- 26.4x
- P/B
- 4.83x
- ROE
- 21.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0L8.F undervalued?
Graham number0L8.F trades 138.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lantheus Holdings Inc fundamental analysis
No fundamental analysis for Lantheus Holdings Inc yet.
Lantheus Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to…
Full company profileLantheus Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lantheus Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 302M | 331M | 343M | 347M | 339M | 425M | 935M | 1.30B | 1.53B | 1.54B | 1.54B |
| Gross Profit | 138M | 162M | 175M | 175M | 139M | 188M | 582M | 710M | 988M | 942M | 955M |
| Operating Income | 50.2M | 51.9M | 64.5M | 51.7M | -4.20M | -76.1M | 36.2M | 365M | 449M | 316M | 285M |
| EBITDA | - | 77.3M | 80.9M | 55.6M | 22.7M | -25.0M | 33.9M | 491M | 515M | 404M | 473M |
| Net Income | 26.8M | 123M | 40.5M | 31.7M | -13.5M | -71.3M | 28.1M | 327M | 312M | 234M | 288M |
| EPS | - | 3.27 | 1.05 | 0.81 | -0.20 | -1.05 | 0.42 | 4.77 | 4.56 | 3.52 | 4.40 |
| Balance Sheet | |||||||||||
| Total Assets | 256M | 384M | 440M | 406M | 870M | 864M | 1.32B | 1.65B | 1.98B | 2.23B | 2.46B |
| Total Liabilities | 362M | 361M | 369M | 291M | 356M | 399M | 874M | 835M | 892M | 1.14B | 1.10B |
| Shareholders' Equity | -107M | 23.3M | 71.0M | 115M | 514M | 464M | 447M | 816M | 1.09B | 1.09B | 1.36B |
| Cash & Short-term Investments | 51.2M | 76.3M | 113M | 92.9M | 79.6M | 98.5M | 416M | 714M | 913M | 359M | 684M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 49.6M | 54.8M | 61.2M | 80.4M | 16.4M | 53.9M | 282M | 298M | 545M | 390M | 426M |
| Capital Expenditure | 7.40M | 17.5M | 20.1M | 22.1M | 12.5M | 12.1M | 278M | 39.2M | 79.6M | 41.5M | 17.7M |
| Free Cash Flow | - | 37.2M | 41.1M | 58.3M | 3.92M | 41.8M | 263M | 259M | 465M | 349M | 408M |
| Ratios | |||||||||||
| ROE | - | 529.8% | 57.1% | 27.6% | -2.6% | -15.3% | 6.3% | 40.0% | 28.7% | 21.4% | 21.2% |
| ROA | 10.5% | 32.1% | 9.2% | 7.8% | -1.5% | -8.3% | 2.1% | 19.8% | 15.8% | 10.5% | 11.7% |
| Net Profit Margin | 8.9% | 37.2% | 11.8% | 9.1% | -4.0% | -16.8% | 3.0% | 25.2% | 20.4% | 15.2% | 18.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Lantheus Holdings Inc dividends
Lantheus Holdings Inc has not paid dividends in the last 9 fiscal years.
Who owns Lantheus Holdings Inc
- Insiders 1.73%
- Institutions 98.27%
- Public & others 0.00%
- Shares outstanding 65.4M
- Free float 58.7M
Lantheus Holdings Inc company profile
- Company name
- Lantheus Holdings Inc
- Ticker
- 0L8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,193
- Fiscal year end
- December
- Address
- 201 Burlington Road, Bedford, MA, United States, 01730
- Phone
- 978 671 8001
- Website
- lantheus.com
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Lantheus Holdings Inc management
10- Ms. Mary Anne HeinoCEO & Executive Chairperson · born 1960
- Mr. Robert J. Marshall Jr., CFACFO & Treasurer · born 1966
- Mr. Daniel M. NiedzwieckiChief Administrative Officer, General Counsel & Corporate Secretary
- Ms. Amanda M. MorganChief Commercial Officer · born 1979
- Dr. Ludger Dinkelborg Ph.D.Head of Research & Development · born 1963
- Mr. Neil HollandVP of Business Insights & Operations
- Ms. Kimberly BrownChief Accounting Officer · born 1990
- Ms. Dorothy BarrSenior VP of Manufacturing & Technical Operations
- Ms. Lee Anne HoweChief Information Officer
- Mr. Mark Richard KinarneyVice President of Investor Relations